ThromboGenics enrolls first patient in phase 1 clinical study evaluating THR-149
ThromboGenics announces it has successfully enrolled the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating safety of THR-149 in the treatment of DME. THR-149 is a novel plasma kallikrein inhibitor generated using Bicycle Therapeutics’ Bicycles® technology platform. May 25, 2018